We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Centurion Res | LSE:CEN | London | Ordinary Share | GB00B3ZNRX66 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.645 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
12/11/2012 08:54 | So, here we are!!! | negotiated_raid | |
12/11/2012 08:50 | I'll try again...! | wow400 | |
12/11/2012 08:46 | Nice one simon.The fightback starts,long term good. | flojo | |
12/11/2012 08:44 | Online trading now running. 0.8-1p online | 34simon | |
12/11/2012 08:39 | Closed, Please go to: | wow400 | |
26/6/2008 07:31 | OK JIM-Thanks. | p@ | |
26/6/2008 07:31 | OK JIM-Thanks. | p@ | |
25/6/2008 14:25 | p@t CEN is no more. It is now Paion(PAI)which is up as I write. My shares are in a nominee account but I haven't got the new PAI ones yet | jimcar | |
21/6/2008 06:39 | Thanks jim i hope i get the new certificate, would you please tell me when you receive yours ,thanks P@. | p@ | |
20/6/2008 21:30 | p@ The vote has already happened, see below. 99.92% is pretty convincing. I think the president of North Korea got 100% in 1962 but that was to keep him in office, not get rid of them as for the CEN board. I dobt Paion cold be worse. FOR IMMEDIATE RELEASE 28 May 2008 RECOMMENDED ACQUISITION OF CENES PHARMACEUTICALS PLC ('CENES') BY PAION AG ('PAION') BY WAY OF SCHEME OF ARRANGEMENT RESULTS OF GENERAL MEETING AND COURT MEETING The directors of CeNeS are pleased to announce that, at the Court Meeting and the General Meeting held today, all the resolutions contained in the relevant notices of meeting were passed by the requisite majorities. Subject to the Court sanctioning the Scheme and approving the Reduction, and the satisfaction or waiver of the other conditions to the Scheme, the Scheme is expected to become Effective on 23 June 2008. POLL RESULT FOR THE COURT MEETING The resolution proposed at the Court Meeting to approve the Scheme was approved by way of a poll of the holders of Scheme Shares. The result of the poll was as follows: Number of Scheme Shares voted for: 6,948,687 99.92% Number of Scheme Shares voted against: 5,417 0.08% Number of Scheme Shareholders voting for: 319 94.38% Number of Scheme Shareholders voting against: 19 5.62% PROXY VOTES FOR THE GENERAL MEETING The General Meeting which immediately followed the Court Meeting was held to consider a special resolution to authorise the CeNeS Directors to take all actions to carry the Scheme into effect, approve amendments to CeNeS's articles of association and approve the Reduction. The resolution was put to the General Meeting and approved on a show of hands. The proxy votes received for the General Meeting were as follows: Number of CeNeS Shares voted for: 6,625,455* 99.91% Number of CeNeS Shares voted against: 5,231 0.08% Number of CeNes Shares voted abstention: 556 0.01% | jimcar | |
20/6/2008 16:48 | Thanks JIM I have some of these but they went off my radar and i was awaiting bid acceptance documents. Don,t we get a vote then? | p@ | |
20/6/2008 09:50 | p@ It shouldn't come as a shock to you if you have any interest in the company Key Dates The last day of dealings in CeNeS Shares is expected to be 19 June 2008. The Court Hearing to sanction the Scheme and approve the Reduction is scheduled for 20 June 2008 and, subject to the satisfaction of the conditions to the Scheme, the Effective Date of the Scheme is expected to be 23 June 2008. On the Effective Date, trading in CeNeS Shares on AIM will be cancelled and the Trustee will be issued New Paion Shares for onward distribution to CeNeS Shareholders. It is expected that dealings in the New Paion Shares on the Frankfurt Stock Exchange will commence on 24 June 2008, and dealings in the New Paion Shares on AIM will commence on 25 June 2008. Enquiries: CeNeS Pharmaceuticals plc Neil Clark, CEO | jimcar | |
20/6/2008 08:58 | suspended!!!! | p@ | |
17/6/2008 13:18 | Is E Jones still around? Was just wondering seeing that guy kill his kids in Wales and remembered E Jones was a karate expert and wondered if he knew the geyser? Assume it is a small world in karate sports events? Really awful situation. | dunderheed | |
17/6/2008 07:25 | Who could it be that is involved with this disaster that is getting these shares.. | kalingalinga | |
01/5/2008 19:49 | If the takeover price was equivalent to 48.9p based on the German share price, how does one obtain the daily movement to that price. Only then can one judge if one is going to make anything, we may find their price is worse than Cenes !!!! I see the Cenes is 32p today, which is equivalent to 1/30th before the recapitalisation, ie a penny share !!! | onlybuyrubbish | |
01/5/2008 16:48 | I have a sneeky suspicion that it could be worth buying the shares at this discounted price because only small selling has caused the fall.I cannot get a quote on Paeion,so I believe some small holders are just giving up and there is now a BIG DISCOUNT TO THE TAKEOUT PRICE .I am tempted to buy a few,any comments would be appreciated. | parsons | |
23/4/2008 18:08 | The following comments about AZM could well be said about M6G and CEN: Alizyme (AZM) Failure for Renzapride EST: NA, REC: NEGATIVE We have previously been negative on the company (6 March) based on its Phase III ready obesity drug, Cetilistat, where we feel there is limited evidence that it will be a commercial success given that several other obesity drugs have failed to forge a blockbuster market. The company has now announced that it will be withdrawing Renzapride for irritable bowel syndrome having shown that it has limited benefit over placebo. This is further evidence that biotech companies should out-licence drugs after Phase II proof of concept and leave the Phase III trials to big pharma. The company is under pressure to secure a deal on cetilistat, which we believe should have been secured after PhaseII trials if the drug really held the blockbuster potential that has been widely cited. | sicilian_kan | |
10/4/2008 16:57 | Looks like a disaster to me. 1. How good the deal is will depend on whether or not Paion's shares can hold up. Shareholders will only get the equivalent of 48.9p IF they can sell their shares for that value once their receive the new ones. 2. Paion's share price is likely to fall. Their shareholders will know that there will be a mass exodus of CEN shareholders selling a vast chunk of their new company and driving down the price. Look at OXB to see how their share price fell, partly contributed to by newly acquired Oxxon shareholders selling out after the deal. Plus there is the credit crunch still biting on bios. 3. So although today's equivalent is a 48.9p deal per share, it may well be you get significantly less than that if you hold, hence today's poor share price reaction. | sicilian_kan | |
10/4/2008 12:29 | I presume the Paion shares would be subject to a lock-in period? | the_doctor | |
10/4/2008 11:58 | lob let's hope reaction to renz better than this deal for cenes!! | dunderheed | |
10/4/2008 11:54 | I didnt think they'd pay a lot, but I thought it would go for a bit more than that! | the_doctor | |
10/4/2008 11:49 | Thinking the same gbh - long gone from here - but my heart goes out to all you long termers - very disapointing!! | dunderheed |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions